GeneCentric Therapeutics has recently secured $8 million in new funding to advance its RNA-based liquid biopsy platform. The financing will support the development and commercialisation of GeneCentric’s platform, which enables non-invasive tumour profiling to guide treatment decisions and monitor disease progression. The funding reflects the growing investor enthusiasm for RNA-driven diagnostics in precision oncology, according to GlobalData.
GeneCentric’s technology harnesses gene expression signatures from circulating RNA to deliver dynamic, real-time insights into tumour biology through a simple blood draw. By moving beyond DNA-centric approaches, GeneCentric’s RNA platform is designed to offer a more functional and comprehensive snapshot of cancer activity, positioning it as a valuable tool in both drug development and clinical decision-making.
Graysen Vigneux, Medical Analyst, GlobalData, comments: “The strong investor response to GeneCentric’s platform highlights a growing recognition that RNA-based diagnostics are critical to the future of oncology. RNA captures the functional state of tumours, enabling clinicians to better match therapies and monitor evolving resistance mechanisms. This marks a clear shift toward more nuanced and adaptive approaches in cancer care.”
RNA-based liquid biopsy represents an emerging frontier in cancer diagnostics, complementing DNA analysis by capturing gene activity and tumour phenotype in real time. GeneCentric’s platform is powered by its proprietary Tumour Functional Taxonomy (TFT), a classification system that segments tumours based on RNA expression profiles to identify optimal therapeutic strategies.
Vigneux adds: “The investment round reflects broader momentum in the oncology diagnostics space, where pharmaceutical companies and investors alike are seeking tools that enhance precision medicine. As therapies become increasingly targeted, the need for diagnostics that can keep pace with tumour evolution is more urgent than ever.”
GeneCentric plans to utilise the funding to expand its biomarker development programs, support regulatory and commercial pathways, and accelerate partnerships with biopharma companies. With this capital, the company aims to establish its RNA-based liquid biopsy as a central tool in both clinical and research settings.
Vigneux concludes, “RNA diagnostics are gaining traction because they answer questions DNA can’t—particularly around how a tumour behaves at a given moment. GeneCentric is well-positioned to capitalise on this trend, offering a platform that not only informs therapy selection but could also unlock new companion diagnostic opportunities.”
